Published in Cancer Weekly, November 23rd, 1998
The data were presented at the Biologic Principles for the Therapy of Human Colon Cancer Conference, held in San Diego, California, November 7, 1998, and hosted by the University of Texas M.D. Anderson Cancer Center of Houston, Texas.
In patients with advanced cancers, SU5416 appeared to be very well-tolerated with minimal side effects, researchers reported. While safety is the primary endpoint of this Phase I trial, preliminary (and, at this point, anecdotal) data indicate that SU5416 may have clinical activity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.